EyePoint Pharmaceuticals, Inc., a company focused on improving life quality for severe eye condition patients, has revealed promising safety data for its key product candidate EYP-1901.
Updated results from a subgroup analysis of a phase 1/2 trial showed that ifinatamab deruxtecan (I-DXd) continues to demonstrate durable responses in patients with heavily pretreated advanced small cell lung cancer.
This article summarized the latest R&D progress of Somatostatin, the Mechanism of Action for Somatostatin, and the drug target R&D trends for Somatostatin.
Bristol Myers Squibb's experimental LPA1 Antagonist showed promising results in reducing the rate of lung function decline in the Progressive Pulmonary Fibrosis group in a phase 2 clinical trial.